IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, December 20, 2018, 17.35 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on December 20, 2018.

Reason for the notification | Downwards crossing of the 3% threshold further to the disposal of shares –and thus voting rights
---|---
Persons subject to the notification requirement | IBA SA, issuer
Persons that dispose of voting rights | Capfi Delen Asset Management NV
Transaction date | 17/12/2018
Threshold that is crossed (in %) | 3%
Denominator | 30 122 528
Voting rights (number) | 793 365
Voting rights (%) | 2.63 %
Chain of control | I. Capfi Delen Asset Management NV, a company incorporated under Belgian law is directly controlled by Bank Delen NV, a company incorporated under Belgian law.
II. Bank Delen NV is directly controlled by Delen Investments Comm. VA, a company incorporated under Belgian law.
III. Delen Investments Comm. VA is directly controlled by Finaxis NV, a company incorporated under Belgian law.
IV. Finaxis NV is directly controlled by Ackermans & Van Haaren NV, a company incorporated under Belgian law.
V. Ackermans & Van Haaren NV is directly controlled by Scaldis Invest NV, a company incorporated under Belgian law.
VI. Scaldis Invest NV is directly controlled by Belfimas NV, a company incorporated under Belgian law.
VII. Belfimas NV wordt rechtstreeks gecontroleerd door Cellfloor SA, a company incorporated under Luxembourg law.
VIII. Cellfloor SA is directly controlled by Apodia International Holding BV, a company incorporated under Dutch law.
IX. Apodia International Holding BV is directly controlled by Palamount NV, a company incorporated under the law of the Netherlands Antilles.
X. Palamount NV is directly controlled by the foundation stichting administratiekantoor “Het Torentje”, incorporated under Dutch law.
XI. The foundation Stichting Administratiekantoor “Het Torentje”, is the ultimate controlling shareholder.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA
Stephanie Bauwin
Legal Counsel
+32 10 203 924 (or +32 10 203 950)
Stephanie.bauwin@iba-group.com